Skip to content

S. 2510 · 118th Congress (2023–2025)

RAPID Reserve Act

This bill requires the Department of Health and Human Services to contract with drug manufacturers to ensure adequate supplies of critical drugs that have vulnerable supply chains. (Under the bill, drugs are considered critical if they are likely to be needed during a public health emergency or if a shortage would pose a significant threat to the health care system or at-risk populations.)

Contracted drug manufacturers must agree to (1) maintain at least a 6-month reserve of the active ingredient in a critical drug and of the finished product and to regularly replenish these reserves, (2) produce the ingredient and drug in a manner and quantity as specified in the contract, and (3) agree to transfer portions of the reserve, if necessary, to other manufacturers to meet manufacturing needs and allow HHS to control the allocation of reserves in the event of a public health emergency or other threat.

HHS must publish a list of critical drugs and issue guidance on the criteria for determining this list and awarding contracts. HHS must give preference to domestic manufacturers for contracts.

In addition, the Government Accountability Office must report on the capacity of domestic manufacturing with respect to critical drugs, including the ability to manufacture different dosage forms and drugs with various characteristics.

Show official title

A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

This is S. 2510’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Gary C. Peters (D-MI)
Cosponsors
5 cosponsors

2 original · 3 later

  1. Sen. Sherrod Brown (D-OH)· Original · Jul 26, 2023
  2. Sen. Marsha Blackburn (R-TN)· Original · Jul 26, 2023
  3. Sen. Ted Budd (R-NC)· Later · Oct 4, 2023
  4. Sen. Joni Ernst (R-IA)· Later · Oct 19, 2023
  5. Sen. Peter Welch (D-VT)· Later · Oct 19, 2023
Policy area
Health
Subjects
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Government information and archives
  • Government studies and investigations
  • Manufacturing
  • Prescription drugs
  • Public contracts and procurement
  • Strategic materials and reserves

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources
  3. Expired

    Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jul 26, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (3)
  1. RAPID Reserve Act

    Display title, Short title · Introduced in Senate

  2. Rolling Active Pharmaceutical Ingredient and Drug Reserve Act

    Short title · Introduced in Senate

  3. A bill to improve supply chain resiliency for critical drug products with vulnerable supply chains and ensure that reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions in the event of drug shortages or public health emergencies.

    Official title · Introduced in Senate